Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Review Decision On sNDA For Actelion’s Tracleer Awaits Finalized REMS

This article was originally published in The Pink Sheet Daily

Executive Summary

An FDA “complete response” letter says the REMS the firm submitted in September 2008 must be finalized and approved before the agency can act on the expanded indication.
Advertisement

Related Content

PAH Market Heats Up: New Approvals For Actelion, United Therapeutics
PAH Market Heats Up: New Approvals For Actelion, United Therapeutics
PAH Market Snapshot: Actelion’s Tracleer Faces Stiffer U.S. Competition
PAH Market Snapshot: Actelion’s Tracleer Faces Stiffer U.S. Competition
Risk Management Plans Are In Fact A “Big Deal,” FDA Tells Gilead
Risk Management Plans Are In Fact A “Big Deal,” FDA Tells Gilead
Actelion Adds to PAH Franchise with IV drug from GeneraMedix
Actelion Vows To Keep PAH Lead, Despite First-Quarter Dip
Retroactive REMS

Topics

Advertisement
UsernamePublicRestriction

Register

PS069153

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel